Nelistotug

Phase 2Small molecule

GSK

Nelistotug is one of 103 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

NeoplasmsActive, not recruiting

Neoplasms, Head and NeckActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

NeoplasmsPhase 1

Active, not recruiting

Neoplasms, Head and NeckPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Nelistotug

GSK

Phase 2

1 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Remeron

OOrganon and Co

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05565378

Q3 2027

Phase 1Active, not recruiting

Neoplasms

NCT05277051

Q4 2027

Phase 2Active, not recruiting

Neoplasms, Head and Neck

NCT06062420

Clinical

Trials by Indication[1]

Lung Cancer1 trial

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05565378·351 enrolled

Non-Small Cell Lung Cancer1 trial

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Completed· GSK logo

GSK·Phase 2·NCT06926673·62 enrolled

Neoplasms1 trial

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT05277051·152 enrolled

Neoplasms, Head and Neck1 trial

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06062420·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nelistotug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nelistotug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nelistotug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Nelistotug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Neoplasms1 trial

Neoplasms, Head and Neck1 trial

References

Drug Info

Quick Facts

Related News